Samu New HCV magunguna
FDA ta yarda da maganin jiyya na cutar Cutar cutar C a farkon shekarun 1990 lokacin da interferon-alfa ya kasance mai samuwa a matsayin mako guda uku na injin HCV. A cikin shekaru ashirin da suka wuce, interferon ko gurbin da ya canza, ya kasance tare da ko ba tare da maganin ribavirin ba, ya zama kula da maganin cutar da ciwon ciwon ciwon ƙwayar cutar ta hanyar haɓaka maganin cutar ta mutum mai cutar.
Wannan farfadowa na da wuya a yi haƙuri, yana da ciwo mai yawa don har zuwa shekara guda, kuma ya sami kashi 6% -54% kawai. A bayyane yake, ana buƙatar magani mafi kyau.
A shekara ta 2011, FDA ta amince da magungunan farko wadanda suka dace da kayan aikin cutar. Wadannan sune masu hana masu protease HCV: boceprevir da telaprevir. Sun kasance masu tasiri wajen dakatar da maganin hoto, amma saboda bayyanar maganin maganin hoto na maganin hoto, sun bukaci a gudanar da su tare da peginterferon da ribavirin. Koda yake duk da cewa yawan adadin da aka samu ya kai kashi 69% -74%, sakamakon cutar na sau uku sun haɗu da marasa lafiya. Wadannan magunguna basu da amfani a Amurka a yau.
Na farko babban nasara ya zo a shekarar 2013 tare da yarda da sofosbuvir da simeprevir. Kodayake an yarda dasu da farko don amfani dashi tare da jimlarar kwayar cutar genotype 1, amfani da lakabi na biyu a hade ba tare da kullun ba , nan da nan ya zama babban amfani.
Gwargwadon nasara sun kai 90% ko mafi girma; da kuma guje wa interferon yana nufin cewa an dakatar da farfadowa a cikin makonni 12-24 na tsawon lokacin magani. Duk da haka, wadannan wakilan suna da tsada sosai kuma wasu rashin damuwa da yanayin rashin ciwon haifa C har yanzu ana buƙatar peginterferon (MEDICAL INFORMATION).
Wannan ya kasance matsayi na HCV har zuwa Oktoba 2014 tare da amincewa da wani nau'i na kwamfutar hannu guda daya na haɗin sofosbuvir da jagoranci na (HARVONI). Wannan kwamfutar ta hade yana da tasiri sosai a cikin jinsin 1 da 4 ba tare da wajibi na peginterferon ko ribavirin ba. Ya kasance mafi yawan maganin ilimin cutar hepatitis C a Amurka. Amma, akwai wasu muhimman bayanai masu muhimmanci. Tun da yake bai kamata a yi amfani da sofosbuvir ga marasa lafiya da ciwon ƙwayar koda mai tsanani (haɓakar halittar halitta ba kasa da 30 mL / min), wannan tsarin kwamfutar ta guda ɗaya yana da wannan ƙuntatawa. Har ila yau, ba magani ba ne ga wadanda suka dauki Amiodarone, magani na zuciya na zuciya. Masu kwantar da hanzari na Proton (Prevacid, Neium, da dai sauransu) na iya rage ingancin wannan magani kuma ya kamata a yi aiki tare.
Bayan 'yan daga baya a shekarar 2014, AbbVie ya sanar da amincewar FDA akan maganin miyagun ƙwayoyi guda uku da ake kira Viekira Pak (VIEKIRA PAK). Wannan hade ya ƙunshi biyu, sau ɗaya kowace rana, magungunan da aka tsara tare da su: Ombitasvir da Paritaprevir da magani guda biyu Dasabuvir. An kirkiro Paritaprevir tare da magani mai mahimmanci, ritonavir, don bunkasa ikon Paritaprevir.
A ƙarshe, don cututtuka na 1a, an hade wannan haɗin tare da ribavirin sau biyu. Wannan haɗuwa yana da matukar damuwa a cikin kwayar cutar 1 tare da ko ba tare da cirrhosis ba. Wannan haɗin yana da lafiya kuma mai tasiri a marasa lafiya da cirrhosis da aka biya, amma bazai da lafiya ga waɗanda suke da alamun tantancewa ( Gargaɗi ) ( Menene ya kashe marasa lafiya da cirrhosis? ). Abubuwan da suka fi dacewa da wannan farfadowa sune wasu magungunan maganin miyagun ƙwayoyi masu magungunan magani saboda mummunan ritonavir da adadin kwayoyi da ake buƙatarwa a kowace rana.
A karshen shekarar 2015, sabuwar magani da FDA ta amince da shi shine Daclatasvir (DACLATASVIR).
Wannan magani ne tare da HCV genotype reactivity kama da sofosbuvir amma yana da magunguna daban-daban, don haka bada wadannan magunguna guda biyu na iya bada izinin kusan dukkanin kwayoyin HCV don amsa ba tare da amfani da peginterferon ko ribavirin ba, amma an bada shawarar don genotype 3 musamman . Akwai wasu hulɗar miyagun ƙwayoyi tare da Daclatasvir, don haka shawara da likita ko likitan magunguna suna bada shawara.
Sauran sababbin magungunan ƙwayoyin cutar Hizitis C ne ake tsammani a farkon 2016. Wadannan zasu kasance batun rahoton mai zuwa. Za ku iya samun bayani game da cutar hepatitis C daga Asusun Amincewa ta Amirka (ALF)